Tag: huonslab

huonslab

Latest News

Huons Group consolidates R&D, production capabilities for future growth

Huons Group is set to bolster its competitiveness by going beyond a mere overhaul of subsidiaries, with a management shake-up and internal consolidation focusing on the core capabilities of its bio and pharmaceutical sectors, while efficiently reorganizing its internal finance resources.

2026.6.24

Huonslab’s Hydizyme enters final stages of commercialization with biologics license application submission

Huonslab has entered the final stage for the commercialization of its recombinant human hyaluronidase, with the aim of receiving approval in the second half of 2026.

2025.12.24

Most popular

Established in 2018, Huonslab operates under the mission to innovate in the human hyaluronidase-based biologics subcutaneous delivery field. [HUONSLAB]

Huonslab study on its Hydiffuze product selected for AACR presentation

A recent study on Huonslab’s Hydiffuze technology has found that the pharmaceutical product demonstrated enhanced bioavailability of subcutaneous infliximab has been selected as a poster presentation at the American Association for Cancer Research...

2025.4.3

Huonslab completes major patent filings for hyaluronidase process in U.S. and EU

Huonslab, a subsidiary of Huons Global and a major player in recombinant human hyaluronidase-based biologics Sub-Q delivery, announced on Nov. 11 that it has completed patent filing and examination requests for its recombinant human hyaluronidase...

2024.11.11

Huonslab scores positive result in nonclinical trial of drug co-formulated with Hydiffuze

Huonslab is accelerating the development of a drug that uses Hydiffuze to enhance patient convenience in subcutaneous injections (SC).

2024.9.4

Huonslab's HLB3-002 approved for clinical trials

Huonslab's HLB3-002, a genetic recombinant hyaluronidase candidate, has been approved for clinical trials, with potential applications in cosmetic procedures, dermatology, pain and edema treatment.

2024.8.7

Huonslab files for patent on manufacturing method for hyaluronidase drug

The research subsidiary of biopharmaceutical firm Huons Global said it has filed for a patent on the manufacturing method of its human genetic recombinant hyaluronidase candidate.

2024.7.23

Additional test proves efficacy of Huonslab's HLB3-002

Huonslab's HLB3-002, a human genetic recombinant hyaluronidase candidate, produced meaningful results confirming its efficacy, the Korean company said Tuesday.

2023.10.24